At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 49 enrolled
Drug / intervention
Tenofovir (TFV) IVR +1 moredrug
Likely dose
Tenofovir (TFV) IVR 1.4 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Sep 13, 2018·Updated Nov 13, 2025
In Brief
A Phase 1 clinical trial evaluating Tenofovir (TFV) IVR and Placebo IVR for HIV Infections. Completed, enrolled 49 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of a 90-day intravaginal ring (IVR) containing tenofovir (TFV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartJan 2019
Primary CompletionSep 2019
TodayJul 2026
First PostedSep 13, 2018
Enrollment StartJan 2, 2019
Primary CompletionSep 25, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.8 years ago
Interventions
Tenofovir (TFV) IVRdrug
Contains 1.4 g TFV
Placebo IVRdrug
Contains placebo